肾移植受者口服钙负荷试验中的甲状旁腺激素抑制特征
该单中心前瞻性队列研究纳入657例肾移植受者,在术后3个月和12个月行口服钙负荷试验,评估口服钙介导的PTH抑制(CMPS)轨迹及其与术后第一年PTH控制的关系。术后3个月71%患者存在甲状旁腺功能亢进,中位CMPS为31%;基线CMPS较高者12个月PTH显著更低(87 vs. 99 pg/ml),提示甲状旁腺反应性和钙生物利用度均与有利结局相关。
要点
- 肾移植术后3个月甲状旁腺功能亢进常见(71%),中位CMPS为31%。
- 基线CMPS较高与12个月PTH更低独立相关(87 vs. 99 pg/ml)。
- 口服钙负荷试验或有助于PT-HPT亚型分层和个体化管理。
核心结论
- 肾移植术后3个月口服钙介导的PTH抑制与一年时更低的PTH水平相关。
- 甲状旁腺腺体反应性和钙生物利用度均与PT-HPT的有利结局相关。
- 该试验可能有助于对PT-HPT亚型进行分层以指导个体化管理。
研究设计与样本
- 单中心前瞻性队列研究,纳入657例肾移植受者。
- 在术后3个月(M3)和12个月(M12)行口服钙负荷试验。
- 评估指标包括实测肾小球滤过率(mGFR)、骨转换标志物和双能X线吸收测定法。
主要发现
- M3时71%患者存在甲状旁腺功能亢进,中位CMPS为31%。
- 30%患者PTH抑制受损与离子钙升高钝化相关,提示肠道钙吸收受损。
- 尽管mGFR随时间下降,M12时钙-PTH动力学改善,所有组曲线左移。
- 基线CMPS较高者M12时PTH显著更低(87 vs. 99 pg/ml),尽管初始PTH更高且拟钙剂使用更少(5.5% vs. 12%)。
- 所有组骨密度均增加,基线PTH抑制较高者髋部骨密度增益大于腰椎。
临床怎么用
- 肾移植术后早期可考虑行口服钙负荷试验评估CMPS以辅助PT-HPT风险分层。
- 基线CMPS较高提示一年后PTH控制更佳,可减少不必要的拟钙剂使用。
- 对CMPS受损者需关注肠道钙吸收不良并个体化调整管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Post-kidney transplant (KT) hyperparathyroidism (PT-HPT) is common and linked to adverse outcomes, yet the contributions of calcium bioavailability and parathyroid responsiveness remain poorly defined. Here, we studied the trajectory of oral calcium-mediated PTH suppression (CMPS) in PT-HPT and its association with PTH control in the first year post-KT. METHODS: This single-center prospective cohort study evaluated 657 KT recipients at 3 (M3) and 12 (M12) months post-KT with an oral calcium loading test, and assessed measured glomerular filtration rate (mGFR), bone turnover markers, and dual X-ray absorptiometry. RESULTS: At M3, hyperparathyroidism was evident in 71% patients, with a median CMPS of 31%. Impaired PTH suppression was associated with blunted increases in ionized calcium in 30% of patients, suggesting impaired intestinal calcium absorption. Despite a decline in mGFR over time, calcium-PTH dynamics improved by M12, with a leftward shift in the curve across all groups. Patients with higher baseline CMPS had significantly lower PTH at M12 (87 vs. 99 pg/ml), despite higher initial PTH and less frequent calcimimetic use (5.5% vs. 12%). Bone mineral density increased across all groups, with greater gain at the hip than the lumbar spine in patients with higher baseline PTH suppression. Higher baseline CMPS was independently associated with lower M12 PTH levels, after adjusting for potential confounders. The association remained significant in a sensitivity analysis excluding patients with blunted increases in serum ionized or urinary calcium suggestive of calcium absorption. CONCLUSIONS: Oral calcium-mediated PTH suppression at M3 post-KT was linked to lower PTH levels at one year, suggesting that both parathyroid gland responsiveness and calcium bioavailability are associated with favorable outcomes in PT-HPT. This test may also help stratifying PT-HPT subtypes for tailored management.
引用
- Desenclos J, Halimi C, Vidal-Petiot E, et al. Parathyroid hormone suppression profiles following oral calcium challenge in kidney transplant recipients. Kidney Int. 2025. PMID: 41456651. doi:10.1016/j.kint.2025.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。